Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Agile Therapeutics Company Profile (NASDAQ:AGRX)

Consensus Ratings for Agile Therapeutics (NASDAQ:AGRX) (?)
Ratings Breakdown: 6 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.75 (54.09% upside)

Analysts' Ratings History for Agile Therapeutics (NASDAQ:AGRX)
Show:
DateFirmActionRatingPrice TargetActions
5/14/2015Cantor FitzgeraldReiterated RatingBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/2/2015FBR & Co.Initiated CoverageOutperform$17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/27/2015Cantor FitzgeraldReiterated RatingBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/30/2014Sterne Agee CRTInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/18/2014Sterne Agee CRTInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2014Cantor FitzgeraldInitiated CoverageBuy$17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2014William BlairInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2014Janney Montgomery ScottInitiated CoverageBuy$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2014RBC CapitalInitiated CoverageOutperform$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/25/2013 forward)